With its many years of experience in applying immunochemical analysis to clinical diagnostics and the research field, Cygnus has assembled a comprehensive menu of reagents and test kits designed to meet the challenges faced by biopharmaceutical companies in development of analytical methods to detect and fully characterize immune responses in patients.
These robust and proven reagents have been developed to overcome many of the non-specific or false positive reactions that often confuse analysis of patient immune responses. Patient antibodies to the therapeutic drug can cause a variety of problems. When patient antibody binds to the drug it may be more rapidly cleared or even neutralized, as has been reported for proteins like insulin, interferon and others to treat hemophilia.
Immunogenicity of the drug gives the potential for significant hypersensitivity reactions and may even progress to the development of auto-antibodies to the patient’s natural version of that protein as has been reported for the recombinant hormone, erythropoietin. Our well characterized immunospecific reagents can be used for the following purposes: